Catch canine osteoarthritis (OA) at its earliest stages with the innovative OA staging tool.
COAST is an innovative canine OA staging tool designed by a consortium of international experts in veterinary surgery and pain management. With COAST, you can start the conversation about canine OA with pet owners before it sets in, and monitor OA over time. This proactive approach to canine OA can help identify the disease earlier, allowing you to intervene sooner and provide your patients a more comfortable future.
Too often, canine OA goes unnoticed. In its early and mild stages, the signs are so subtle that it’s not always easy to identify that a dog is suffering from canine OA, especially in your clinic.
At home, dogs are more relaxed and more likely to show subtle changes in behavior that their owners can pick up on. It’s important every pet owner knows what to look out for, to help you with early diagnosis and intervention.
With a simple, 3-step process, incorporating this tool as part of your daily clinical routine is easy.
Assess the dog’s overall level of discomfort and posture while stationary and in motion, with input from the pet owner about your patient’s behavior at home.
Determine how much pain there is on manipulation, assess range of movement and take radiographs.
Use the scores to determine the dog’s COAST stage.
COAST incorporates pet owner input from any appropriate clinical metrology instrument (CMI). The Liverpool Osteoarthritis in Dogs Index (LOAD), developed by the University of Liverpool and exclusively distributed by Elanco, is regarded as one of the most comprehensively validated CMIs for canine OA.2-5
Use these tools and resources to help you assess, diagnose and treat OA in your patients.
Inspiring Stories
Canine OA is a progressive disease that can affect dogs during any stage of life.
A multimodal treatment approach begins with pain management using an NSAID.
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
PM-US-19-1929(2)